Oxford Nanopore Technologies plc announced the expansion of the leadership team to support the business in its next phase of growth. Following a comprehensive search process, Nick Keher has been appointed as Director of Oxford Nanopore, effective 22 January 2024. Nick will succeed Tim Cowper, who moves into a new role as Chief Operating Officer ("COO") after performing both the role of CFO and fulfilling most of the responsibilities typically assigned to a COO for the past five years.

Nick is an experienced life sciences CFO, having previously served as CFO of Clinigen Group and Benevolent AI. Prior to his CFO roles he gained extensive experience in the life sciences industry serving as Managing Director and Head of the European healthcare equity research team at Royal Bank of Canada (RBC) and before that held roles at Investec and GSK after switching from practising pharmacy. Nick comes to the role with significant experience of financial leadership of complex, scientific businesses, and has a deep understanding of capital markets.

In his role as CFO, Nick will have responsibility for the Group's finance function and investor relations. In his new role as COO, Tim Cowper will lead the development of Oxford Nanopore's expanding international footprint and operations, including day to day operational functions such as manufacturing, tech transfer, IT, supply chain, global distribution, EHS and set up and management of international facilities. There will be a transition period to ensure a smooth handover and the efficient completion of the Company's 2023 audit and full year financial results.

Going forward in his role as COO, Tim will continue to work closely with the new CFO to drive operational performance and margin enhancement. During the past five years, Nick Keher has been a director of Clinigen Group.